Jennifer C. Schroeder

TL;DR: KA is a potent AHR endogenous ligand that can induce IL6 production and xenobiotic metabolism in cells at physiologically relevant concentrations and it is established that the carboxylic acid group is required for significant agonist activity.

TL;DR: Indoxyl 3-sulfate represents the first identified relatively high potency endogenous AHR ligand that plays a key role in human disease progression and may contribute to toxicity observed in kidney dialysis patients and thus represent a possible therapeutic target.

TL;DR: It is demonstrated that ligand-activated AHR is involved in priming the IL6 promoter through binding to nonconsensus dioxin response elements located upstream of the IL 6 start site, leading to synergistic IL6 expression in the presence of inflammatory signals.

TL;DR: 6,2′,4′-trimethoxyflavone (TMF) is identified and characterized as an AHR ligand that possesses the characteristics of an antagonist having the capacity to compete with agonists, thus effectively inhibiting AHR-mediated transactivation of a heterologous reporter and endogenous targets.

TL;DR: Evidence is provided that several head and neck squamous cell carcinoma cell lines have a level of constitutively bound AHR at the IL6 promoter, allowing for higher basal and readily inducible IL6 transcription.